Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens

Cancer Research

Volumn 60, Issue 2, 2000, Pages 365-371

  Youde, Sarah J ^a   Dunbar, P R Rod ^c   Evans, Eve M L ^a   Fiander, Alison N ^b   Borysiewicz, Leszek K ^a   Cerundolo, Vincenzo ^c   Man, Stephen ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b LLANDOUGH HOSPITAL   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP A ANTIGEN; CD8 ANTIGEN; EPITOPE; HISTOCOMPATIBILITY ANTIGEN; LYMPHOCYTE ANTIGEN; PEPTIDE;

ADULT; ANTIGEN ANTIBODY COMPLEX; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOCOMPATIBILITY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; PHENOTYPE; PRIORITY JOURNAL; RELIABILITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; AMINO ACID SEQUENCE; CARCINOMA IN SITU; CELL SEPARATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; FEMALE; FLOW CYTOMETRY; HLA-A ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; MACROMOLECULAR SUBSTANCES; MALE; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; REFERENCE VALUES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 0034650402     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Boyle, P. Global burden of cancer. Lancet, 349(Suppl. II): 23-26, 1997.
2. zur Hausen, H. Viruses in human cancers. Science (Washington DC), 254: 1167-1173, 1991.
3. Bosch, F. X., Manos, M. M., Munoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Morcno, V., Kurman, R., Shah, K. V., Alihonou, E., Bayo, S., Mokhtar, H. C., Chicareon, S., Daudt, A., Delosrios, E., Ghadirian, P., Kitinya, J. N., Koulibaly, M., Ngelangel, C., Tintore, L. M. P., Riosdalenz, J. L., Sarjadi, Schneider. A., Tafur, L., Teyssie, A. R., Rolon, P. A., Torroella, M., Tapia, A. V., Wahinga, H. R., Zatonski, W., Sylla, B., Vizcaino, P., Magnin, D., Kaldor, J., Greer, C., and Wheeler, C. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst., 87: 796-802, 1995.
4. Crook, T., Morgenstern, J. P., Crawford, L., and Banks, L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J., 8: 513-519, 1989.
5. Vousden, K. H. Interactions between papillomavirus proteins and tumor suppressor gene products. Adv. Cancer Res., 64: 1-24, 1994.
6. Chen, L. P., Thomas, E. K., Hu, S. L., Hellstrom, I., and Hellstrom, K. E. Human papillomavirus type 16 nueleoprotein E7 is a tumor rejection antigen. Proc. Natl. Acad. Sci. USA. 88: 110-114, 1991.
7. Meneguzzi, G., Cerni, C., Kieny, M. P., and Lathe, R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology. 181. 62-69, 1991.
8. Ji, H., Chang, E. Y., Lin, K. Y., Kurman, R. J., Pardoll, D. M., and Wu, T. C. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int. J. Cancer, 78: 41-45, 1998.
9. Fellkamp, M. C. W., Smits, H. L., Vierboom, M. P. M., Minaar, R. M., de Jough, B. M., Drijfhoul, J. W., ter Schegget, J., Melief, C. J. M., and Kast, M. W. Vaccination with cytotoxic T lymphocyte epitope containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol., 23: 2638-2542, 1993.
10. Halpert, R., Fruchter, R. G., Sedlis, A., Butt, K., Boyce, J. G., and Sillman, F. H. Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet. Gynecol., 68: 251-258, 1986.
11. Kiviat, N. B., Critehlow, C. W., Holmes, K. K., Kuypers, J., Sayer, J., Dunphy, C., Surawiez, C., Kirby, P., Wood, R., and Daling, J. R. Association of anal dysplasia and human papillomavirus with immunosuppression and HIV infection among homosexual men. AIDS, 7: 43-49, 1993.
12. Petry, K. U., Scheffel, D., Bode, U., Gabrysiak, T., Kochel, H., Kupsch, E., Glaubitz, M., Niesert, S., Kuhnle, H., and Schedel, I. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int. J. Cancer. 57: 836-840, 1994.
13. Shamanin, V., zur Hausen, H., Lavergne, D., Proby, C. M., Leigh, I. M., Neumann. C., Hamm, H., Goos, M., Haustein, U-F., Jung, E. G., Plewig, G., Wolff, H., and de Villiers, E-M. Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J. Natl. Cancer Inst., 88: 802-811, 1996.
14. Beverley, P. C., Sadovnikova, E., Zhu, X., Hickling, J., Gao, L., Chain, B., Collins, S., Crawford, L., Vousden, K., and Stauss, H. J. Strategies for studying mouse and human immune responses to human papillomavirus type 16. Ciba Found. Symp., 187: 78-86, 1994.
15. Jochmus, I., Osen, W., Altmann, A., Buck, G., Hofmann, B., Schneider, A., Gissmann, L., and Rammensee, H. G. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7 derived peptide. J. Gen. Virol., 78: 1689-1695, 1997.
16. England, R., Tindle, R. W., and Frazer, I. H. Optimisation of human cytotoxic T lymphocyte (CTL) measurement as a prelude to E-7 specific CTL evaluation in cervical cancer patients. In: Programs and Abstracts 15th International Papillomavirus Conference, Queensland, Australia, p. 208, 1996.
17. Ressing, M. E., van Driel, W. J., Celis, E., Sette, A., Brandt, M. P., Hartman, M., Anholts, J. D., Schreuder, G. M., ter Harmsel, W. B., Fleuren, G. J., Trimbos, B. J., Kast, W. M., and Melief, C. J. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A*0201-restricted E7-encoded epitope. Cancer Res., 56: 582-588. 1996.
18. Evans, E. M., Man, S., Evans, A. S. and Borysiewicz, L. K. Infiltration of cervical cancer tissue with human papillomavirus- specific cytotoxic T-lymphocytes. Cancer Res., 57: 2943-2950, 1997.
19. Evans, C., Bauer, S., Grubert, T., Brucker, C., Baur, S., Heeg, K., Wagner, H., and Lipford, G. B. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions. Cancer Immunol. Immunother., 42: 151-160, 1996.
20. Nakagawa, M., Stiles, D. P., Farhat, S., Sisler, J. R., Moss, B., Kong, F., Moscicki, A. B., and Palefsky, J. M. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J. Infect. Dis., 175: 927-931, 1997.
21. Borysiewicz, L. K., Fiander, A., Nimako, M., Man, S., Wilkinson, G. W. G., Westmoreland, D., Evans, A. S., Adams, M., Staecy, S. N., Boursnell, M. E. G., Rutherford, E., Hickling, J. K., and Inglis, S. C. A recombinant vaccinia virus encoding human papillomavirus type 16 and type 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet, 147: 1523-1527, 1996.
22. Nimako, M., Fiander, A. N., Wilkinson, G. W., Borysiewicz., L. K., and Man, S. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Res., 57: 4855-4861, 1997.
23. McMichael, A., and O'Callaghan, C. A new look at T cells. J. Exp. Med., 187: 1367-1371, 1998.
24. Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams. M. G., Bell, J. I., McMichael, A. J., and Davis, M. M. Phenotypic analysis of antigen-specific T lymphocytes. Science (Washington DC). 274: 94-96, 1996.
25. Murali-Krishna, K., Altman, J. D., Suresh, M., Sourdive, D. J., Zajac, A. J., Miller. J. D., Slansky, J., and Ahmed, R. Counting antigen-specific CD8 T cells: a revaluation of bystander activation during viral infection. Immunity, 8: 177-187, 1998.
26. Butz, E. A., and Bevan, M. J. Massive expansion of antigen-specific CD8+ T cells during an acute virus infection. Immunity, 8: 167-175, 1998.
27. Ogg, G. S., Jin, X., Bonhoeffer, S., Dunbar, P. R., Nowak, M. A., Monard, S., Segal, J. P., Cao, Y. Z. RowlanJones, S. L. Cerundolo, V., Hurley, A., Markowitz, M., Ho, D. D., Nixon, D. F., and McMichael, A. J. Quantitation of HIV I specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (Washington DC), 279: 2103-2106, 1998.
28. Romero, P., Dunbar, P. R., Valmori, D., Pittet, M., Ogg, G. S., Rimoldi, D., Chen. J. L., Lienard, D., Cerottini, J. C., and Cerundolo. V. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen- experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med., 188: 1641-1650, 1998.
29. Dunbar, P. R., Ogg, G. S., Chen, J., Rust, N., van der Bruggen, P., and Cerundolo, V. Direct isolation, phenotyping and cloning of low-frequency antigen- specific cytotoxic T lymphocytes from peripheral blood. Curr. Biol., 8: 413-416, 1998.
30. Hogan, K. T., Clayberger, C., Bernhard, K. J., Walk, S. F. Ridge, J. P., Parham, P., Krensky, A. M., and Engelhard, V. H. Identification by site-directed mutagenesis of amino acid residues contributing to serologic and CTL-defined epitope differences between HLA-A2.1 and HLA-A2.3. J. Immunol., 141: 2519-2525, 1988.
31. Pattillo, R A., Hussa, R. O., Story, M. T., Ruckert, A. C., Shalaby, M. R., and Mattingly, R. F. Tumor antigen and human chorionic gonadotropin in CaSki cells: a new epidermoid cervical cancer cell line. Science (Washington DC). 196: 1456-1458, 1977.
32. Cailleau, R., Young, R., Olive, M., and Reeves, W. J., Jr. Breast tumour cell lines from pleural effusions. J. Natl. Cancer Inst., 53: 661-666, 1974.
33. Kast, W. M., Brandt, R. M., Sidney, J., Drijfhout, J. W., Kubo, R. T., Grey, H. M., Melief, C. J., and Sette, A. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and B7 proteins. J. Immunol., 152: 3904-3912, 1994.
34. Lehner, P. J., Wang, E. C., Moss, P. A., Williams, S., Platt, K., Friedman, S. M., Bell. J. I., and Borysiewicz., L. K., Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V β 17 gene segment. J. Exp. Med. 181: 79-91, 1995.
35. Plebanski, M., Allsopp, C. E., Aidoo, M., Reybum, H., and Hill, A. V. Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood. Eur. J. Immunol., 25: 1783-1787, 1995.
36. Dunbar, P., Chen, J., Chao, D., Rust, N., Teisserenc, H., Ogg, G., Romero, P., Weynants, P., and Cerundolo, V. Rapid cloning of tumour specific CTL suitable for adoptive immunotherapy of melanoma. J. Immunol., 162: 6959-6962, 1999.
37. Boursnell, M. E. G., Rutherford, E., Hickling, J. K., Rollinson, H. A., Munro, A. J., Rolley, N., McClean, C. S., Borysiewiez, L. K., Vousden, K., and Inglis, S. C. Construction and characterization of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine, 14: 1485-1494, 1996.
38. Callan, M. F., Tan, L., Annels, N., Ogg, G. S., Wilson, J. D., O'Callaghan, C. A., Steven, N., McMichael, A. J., and Rickinson, A. B. Direct visualization of antigen-specific CD8(+) T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med., 187: 1395-1402, 1998.
39. Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., Roederer, M., and Davis, M. M. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med., 5: 677-685, 1999.
40. Valmori, D., Pittet, M. J., Rimoldi, D., Lienard, D., Dunbar, R., Cerundolo, V., Lejeune, F., Cerottini, J. C., and Romero, P. An antigen-targeted approach to adoptive transfer therapy of cancer. Cancer Res., 59: 2167-2173, 1999.
41. Tan, L. C., Gudgeon, N., Annels, N. E., Hansasuta, P., O'Callaghan, C. A., Rowland-Jones, S., McMichael, A. J., Rickinson, A. B., and Callan, M. F. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J. Immunol., 162: 1827-1835, 1999.
42. Alexandermiller, M. A., Leggatt, G. R., and Berzofsky, J. A. Selective expansion of high avidity or low avidity cytotoxic T lymphocyte and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA, 93: 4102-4107, 1996.
43. Carbone, F. R., Moore, M. W., Sheil, J. M., and Bevan, M. J. Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides. J. Exp. Med., 167: 1767-1779, 1988.
44. Theobald, M., Biggs, J., Dittmer, D., Levine, A. J., and Sherman, L. A. Targeting p53 as a general tumour antigen. Proc. Natl. Acad. Sci. USA, 92: 11993-11997, 1996.
45. Ressing, M. E., Sette, A., Brandt, R. M. P., Ruppert, J., Wentworth, P. A., Hartman, M., Oseroff, C., Grey, H. M., Melief, C. J. M., and Kast, W. M. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201 binding peptides. J. Immunol., 154: 5934-5943, 1995.
46. Alexander, M., Salgaller, M. L., Celis, E., Sette, A., Barnes, W. A., Rosenberg, S. A., and Steller, M. A. Generation of tumor specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7epitope. Am. J. Obstet. Gynecol., 175: 1586-1593, 1996.
47. McNeil, C. HPV vaccine treatment trials proliferate, diversify. J. Natl. Cancer Inst., 89: 280-281, 1997.
48. Van Elsas, A., Van der Burg, S. H., Van der Minne, C. E., Borghi, M., Mourer, J. S., Melief, C. J. M., and Schruer, P. I. Peptide pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stable HLA*0202 binding peptides from the Melan-a/Mart 1 self antigen. Eur. J. Immunol., 26: 1683-1689, 1996.
49. Evans, E. M. L., Borysiewicz, L., and Man, S. Can HPV 16 E7 peptide specific CTL be used for immunotherapy of cervical cancer. Proc. Am. Assoc. Cancer Res., 40: 101, 1999.
50. Yee, C., Savage, P. A., Lee, P. P., Davis, M. M., and Greenberg, P. D. Isolation of high avidity melanoma-reactive CTL from heterogenous populations using peptide-MHC tetramers. J. Immunol., 162: 2227-2234, 1999.
51. Ogg, G. S., Dunbar, P. R., Romero, P., Chen, J., and Cerundolo, V. High frequency of skin homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J. Exp. Med., 188 6: 1203-1208, 1998.
52. Bieganowska, K., Hollsberg, P., Buckle, G. J., Lim, D. G., Greten, T. F., Schneck, J., Altman, J. D., Jacobson, S., Ledis, S. L., Hanchard, B., Chin, J., Morgan, O., Roth, P. A., and Hafler, D. A. Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy. J. Immunol., 162: 1765-1771, 1999.
53. Borysiewicz, L., Fiander, A., Scherf, C., Jasani, B., Borysiewicz, C. A., West, B., Man, S., and Walraven., G. HPV infection and cervical dysplasia in rural sub-Saharan Africa-a pilot study in unselected women of reproductive age in the Gambia. In: Program and Abstracts, 17th International Papillomavirus Conference. Charleston USA, p. 336, 1999.
54. Koutsky, L. A., Holmes, K. K., Critchlow, C. W., Stevens, C. E., Paavonen, J., Beckmann, A. M., Derouen, T. A., Galloway, D. A., Vernon, D., and Kiviat, N. B. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or grade 3 in relation to papillomavirus infection. N. Engl. J. Med., 327: 1272-1278, 1992.
55. Melchers, W., van den Brule, A., Walboomers, J., de Bruin, M., Burger, M., Herbrink, P., Meijer, C., Lindeman, J., and Quint, W. Increased detection rate of human papillomavirus in cervical scrapes by the polymerase chain reaction as compared to modified FISH and Southern-blot analysis. J. Med. Virol., 27: 329-335, 1989.
56. Frazer, I. H., Thomas, R., Zhou, J., Leggatt, G. R., Dunn, L., McMillan, N., Tindle, R. W., Filgueira, L., Manders, P., Barnard, P., and Sharkey, M. Potential strategies utilised by papillomavirus to evade host immunity. Immunol. Rev., 168: 131-142, 1999.
57. Connor, M. E., and Stern, P. L. Loss of MHC class-I expression in cervical carcinomas. Int. J. Cancer, 46: 1029-1034, 1990.
58. Stanley, M. A. Replication of human papillomaviruses in cell culture. Antivir. Res., 24: 1-15, 1994.